New guidance on the care and treatment of patients with inflammatory bowel disease has been produced by the British Society of Gastroenterology (Gut 2011;60:571).
Recommendations on the use of immunosuppressive therapy have been revised and the guidance emphasises smoking cessation to improve outcomes in patients with Crohn’s disease. The guidance also supports once daily administration of mesalazine in maintenance of remission.
To read the full story click here.
Extract taken from PJ Online